Petrelintide: Molecular Structure
Chemical properties, amino acid sequence, and structural analysis
📌TL;DR
- •Molecular formula: C185H305N49O61
- •Molecular weight: 4170 Da
- •Half-life: Approximately 4-7 days (supports once-weekly dosing)
Amino Acid Sequence
55 amino acids
Formula
C185H305N49O61
Molecular Weight
4170 Da
Half-Life
Approximately 4-7 days (supports once-weekly dosing)
Molecular Structure#
Petrelintide is a 36-amino acid peptide based on the human amylin sequence with modifications to improve stability and pharmacokinetics. Native amylin (37 amino acids) is notoriously prone to aggregation and amyloid fibril formation. Petrelintide's engineering overcomes this limitation while preserving amylin receptor binding.
Key Structural Features#
| Feature | Description |
|---|---|
| Peptide length | 36 amino acids |
| Parent hormone | Human amylin (islet amyloid polypeptide) |
| Lipid modification | Fatty acid acylation |
| Half-life extension | Albumin binding via acyl chain |
| Receptor targets | AMY1, AMY2, AMY3 receptors |
| Stability | Engineered to resist amyloid aggregation |
Comparison with Native Amylin and Pramlintide#
Native amylin has a half-life of approximately 13 minutes and requires multiple daily injections (as pramlintide). Petrelintide's acylation extends this to enable once-weekly dosing, a major practical advantage.
| Property | Native Amylin | Pramlintide | Petrelintide |
|---|---|---|---|
| Length | 37 aa | 37 aa | 36 aa |
| Half-life | ~13 min | ~48 min | ~4-7 days |
| Dosing | N/A | 3x daily | Once weekly |
| Aggregation | Prone | Resistant | Resistant |
Pharmacokinetic Properties#
| Parameter | Value |
|---|---|
| Half-life | Approximately 4-7 days |
| Administration | Once-weekly subcutaneous injection |
| Bioavailability | Subcutaneous (specific value not disclosed) |
| Steady state | Expected within 4-5 weeks |
Molecular Context#
Petrelintide belongs to the Metabolic category of research peptides. The molecular properties of Petrelintide determine its pharmacological behavior, including receptor binding, distribution, metabolism, and elimination. Understanding these properties is fundamental to interpreting clinical data and designing research protocols.
Structural Overview#
Petrelintide is characterized as: Petrelintide is a 36-amino acid synthetic peptide analog of human amylin. It features fatty acid acylation that enables albumin binding, extending the half-life to support once-weekly subcutaneous administration. The peptide is designed to overcome the aggregation and stability issues of native amylin while maintaining full receptor activity at AMY1, AMY2, and AMY3 receptors..
Amino Acid Sequence Details#
The amino acid sequence of Petrelintide is: Not publicly disclosed (36-amino acid acylated peptide). This sequence determines the peptide's three-dimensional structure, receptor binding properties, and biological activity.
Pharmacokinetic Profile#
Half-Life: Approximately 4-7 days (supports once-weekly dosing)
The half-life of a peptide influences dosing frequency, duration of effect, and the clinical utility of the compound. Researchers should consider the half-life when designing experimental protocols.
Related Reading#
Frequently Asked Questions About Petrelintide
Explore Further
Disclaimer: For educational purposes only. Not medical advice. Read full disclaimer